Select Language:
A new magnetic resonance imaging platform has been launched at a research, development, and manufacturing facility in China, marking a major milestone for the international healthcare technology company’s open innovation strategy in the country.
Unveiled on August 22, the platform combines advanced MRI application technologies, a library of research sequences, and an all-encompassing software development environment, enabling smooth integration of third-party artificial intelligence algorithms.
The platform provides five key functions: fostering innovative technology development, collaborative creation involving industry, academia, research, and clinical partners, clinical research services, technical training for clinical progress, and support for industry collaborators.
Initial partnerships include leading institutions such as Peking University Shenzhen Hospital and Southern University of Science and Technology.
Focus areas for the platform emphasize pushing the boundaries of MRI technology and clinical treatments, speeding up innovation in high-end medical equipment, transforming medical engineering research, promoting intelligent solutions, and building a collaborative ecosystem among industry, academia, research, and healthcare sectors.
According to the general manager of the Shenzhen-based MRI division, China’s next wave of innovation must embrace openness rather than a closed approach, emphasizing a strong R&D ecosystem.
Established in Shenzhen in 2002, this facility is the company’s first research, development, and manufacturing hub in China. Recently, it announced the delivery of its 10,000th medical device.
In recent years, the company has increased investment in China, optimizing its supply chain and infrastructure. In January, it broke ground on a new high-end medical equipment R&D and manufacturing center in Shenzhen, with a total investment exceeding CNY1 billion (approximately USD140 million). The project is expected to be completed and operational by 2027.




